Login

Forgot password?
Sign up today and your first download is free.
REGISTER

Rx Drugs

October 04, 2018 | Daily News

Pharmacy benefit managers support recommendations by congressional Medicare advisors to update the defunct Competitive Acquisition Program in Part B, but with a twist: PBMs want Medicare administrative contractors to be vendors that subcontract with PBMs to negotiate drug prices.

October 04, 2018 | Daily News

Congressional Medicare advisers say the Competitive Acquisition Program could be used for negotiating prices of drugs administered at inpatient hospitals, and they point to the debate over expensive CAR-T cancer drugs as an example of why CMS might want to expand the scope of the program, should it be revived, beyond outpatient settings.

October 04, 2018 | Daily News

Brand-drug makers' lobbying maneuvers in their failed bid to get Part D donut hole changes included in the opioid legislation could factor into an expected new push by the industry for the changes during the upcoming lame-duck session of Congress.

October 03, 2018 | Daily News

The Senate cleared a massive bicameral package of opioid legislation on Wednesday (Oct. 3) by a vote of 98-1, with Sen. Mike Lee (R-UT) as the sole “no” vote, and Sen. Ted Cruz (R-TX) not voting.

October 02, 2018 | Daily News

FDA warned brand drug makers Tuesday (Oct. 2) that it will alert the Federal Trade Commission (FTC) and Congress if it determines that a citizen petition was submitted primarily to delay approval of a generic drug application.

October 02, 2018 | Daily News

More than 700 hospitals and health systems are asking House and Senate leadership to protect the 340B drug discount program in light of recent regulations and legislative proposals the providers say would “undo more than two decades of bipartisan work” on the safety net.

October 02, 2018 | Daily News

California Governor Edmund Brown (D) signed a bill requiring that pharmacy benefit managers disclose rebates and other pricing information, despite strong opposition from the national pharmacy benefit manager and health insurance lobbies and the California Department of Finance.

October 01, 2018 | Daily News

The new trade deal between the United States, Canada and Mexico gives makers of brand biologics 10 years of data exclusivity, even though Canadian law grants eight years of protection, and the deal includes a “robust scope of product eligibility for protection,” according to a summary from the U.S. Trade Representative Office.

October 01, 2018 | Daily News

In a win for the dialysis industry, California Gov. Jerry Brown (D) on Sunday (Sept. 30) vetoed legislation (SB 1156) that would have limited dialysis pay in commercial insurance to Medicare levels for patients who receive premium assistance from industry-funded charities.

October 01, 2018 | Daily News

FDA on Friday (Sept. 28) issued two draft guidances that agency chief Scott Gottlieb says will lower the cost of drug development, making it easier for sponsors to bring second and third drugs in a class to market.

October 01, 2018 | Daily News

In another step toward bringing competition to an expensive, top-selling rheumatoid arthritis drug, FDA is reviewing Samsung Bioepis’ application for a biosimilar of Humira, according to a release by Bioepis.

October 01, 2018 | Daily News

The Drug Enforcement Administration has placed the first FDA-approved cannabidiol (CBD) drug, Epidiolex, under Schedule V of the Controlled Substances Act, and manufacturer GW Pharmaceuticals says the drug should be available in the next six weeks.

September 28, 2018 | Daily News

The sweeping opioid deal passed by the House Friday (Sept. 28) includes new language aimed at closing a loophole in separate gag-order legislation that requires makers of biologics to report to the Federal Trade Commission settlements that could delay biosimilar competition.

September 28, 2018 | Daily News

HHS on Friday (Sep. 28) announced about $2.6 million in prize money for the KidneyX: Redesign Dialysis competition, and Ed Simcox, HHS chief technology officer, said at a briefing that the while the prize competition can encourage innovation, coordination between FDA and CMS to improve patient access will also be part of the KidneyX initiative.

September 27, 2018 | Daily News

FDA Deputy Commissioner Anna Abram urged compounders to be more proactive in keeping their facilities clean, and issued a revised draft guidance on the issue aimed at helping compounders identify unclean conditions in their facilities and implement corrective actions, as well helping state health agencies on their day-to-day oversight.

September 27, 2018 | Daily News

A provision expanding the sunshine law to require drug and medical device makers publicly disclose payments made to health care providers beyond doctors made it into the final version of an opioid bill unveiled by House and Senate negotiators on Tuesday (Sept. 25), despite opposition from the medical device lobby.

September 26, 2018 | Daily News

The final version of opioid legislation excludes brand-drug industry-backed Part D changes, and now brand lobbyists have set their sights on the lame-duck session for getting Congress to lower the industry’s share of seniors’ drug costs.

September 26, 2018 | Daily News

The final opioid legislation unveiled by House and Senate negotiators late Tuesday (Sept. 25) includes two controversial provisions -- one expanding Medicaid payments for opioid-abuse treatment in large inpatient facilities and another allowing non-physician providers to prescribe a drug used to treat opioid addiction.

September 26, 2018 | Daily News

The final opioid legislation negotiated by House and Senate negotiators includes a number of FDA-focused provisions, including measures to expand the agency’s authorities in international mail facilities; allow the agency to impose certain packaging and disposal requirements for drugs that pose serious risks; and let FDA require labeling changes for drugs when new effectiveness information emerges.

September 26, 2018 | Daily News

The opioid legislation hammered out by House and Senate conferees includes a requirement that HHS, in consultation with FDA and other relevant agencies, develop materials describing the circumstances under which a pharmacist may decline to fill a prescription for a controlled substance.

Pages